Companies

BioNexus Gene Lab Corp

BGLC · CIK 0001737523 · operating

$2.67+5.53%Last updated Feb 27, 8:53 PM

Key Statistics

Valuation

Market Cap$6.44M
P/E
Fwd P/E
PEG
P/S0.68
P/B0.72
EV/EBITDA-0.96
EV/Rev0.24

Profitability

Gross Margin13.56%
Op. Margin-16.55%
Net Margin-16.81%
ROE-19.20%
ROA-15.32%
FCF Margin-25.88%

Financial Health

Current Ratio3.81
Debt/Equity0.25
Free Cash Flow-$2.46M
Div. Yield

Growth & Other

Revenue Growth-2.66%
EPS Growth
Beta2.29
52W High$15.6
52W Low$1.92

About BioNexus Gene Lab Corp

BioNexus Gene Lab Corp operates as a chemical distributor and life sciences services provider primarily serving Southeast Asian markets. The company supplies specialty chemical raw materials used across industrial manufacturing, including polyester resins for composite applications in marine, automotive, aerospace, and construction sectors. Its product portfolio includes thixotropic polyester resins designed for quick-curing applications, general-purpose resins for boat and marine component manufacturing, and pultrusion-grade materials for producing structural elements such as handrails and clean room paneling.

The company operates through three distinct segments: Trading of Industrial Chemicals, Provision of Genomic Screening Services, and Investment Holding. The industrial chemicals segment represents its primary business, distributing polyester resins and related chemical inputs throughout Malaysia, Indonesia, Vietnam, and other Southeast Asian countries. The genomic screening services segment provides non-invasive liquid biopsy testing platforms focused on early biomarker detection, representing a diversification into diagnostic services.

BioNexus Gene Lab maintains a small operational footprint with approximately 30 full-time employees and is headquartered in Kuala Lumpur, Malaysia. The company was incorporated in Wyoming in 2017 and is listed on Nasdaq.

Earnings Per Share (Annual · SEC XBRL)

Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.

Fiscal YearEPS DilutedEPS BasicYoY
2024$-0.09
2023
2022
2021
2020
2019

Latest News

Annual Reports (10-K) · 6 filings

Report DateFiledAccession Number
2024-12-312025-04-150001477932-25-002725SEC ↗
2023-12-312024-04-160001477932-24-002151SEC ↗
2022-12-312023-03-310001477932-23-002002SEC ↗
2021-12-312022-04-060001477932-22-002089SEC ↗
2020-12-312021-03-300001477932-21-001795SEC ↗
2019-12-312020-03-310001477932-20-001729SEC ↗